AR058105A1 - Derivados de piperazina utiles como agonistas de ccr5 - Google Patents
Derivados de piperazina utiles como agonistas de ccr5Info
- Publication number
- AR058105A1 AR058105A1 ARP060104564A ARP060104564A AR058105A1 AR 058105 A1 AR058105 A1 AR 058105A1 AR P060104564 A ARP060104564 A AR P060104564A AR P060104564 A ARP060104564 A AR P060104564A AR 058105 A1 AR058105 A1 AR 058105A1
- Authority
- AR
- Argentina
- Prior art keywords
- piperazine derivatives
- ccr5 agonists
- useful
- useful piperazine
- ccr5
- Prior art date
Links
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 title 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 title 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical class C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000002148 esters Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/255,643 US7825121B2 (en) | 1999-05-04 | 2005-10-21 | Piperazine derivatives useful as CCR5 antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR058105A1 true AR058105A1 (es) | 2008-01-23 |
Family
ID=37872167
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060104564A AR058105A1 (es) | 2005-10-21 | 2006-10-19 | Derivados de piperazina utiles como agonistas de ccr5 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7825121B2 (https=) |
| EP (1) | EP1951708B1 (https=) |
| JP (2) | JP2009512705A (https=) |
| KR (1) | KR20080058486A (https=) |
| CN (1) | CN101326178A (https=) |
| AR (1) | AR058105A1 (https=) |
| AU (1) | AU2006306491B2 (https=) |
| BR (1) | BRPI0617731A2 (https=) |
| CA (1) | CA2626565A1 (https=) |
| EC (1) | ECSP088378A (https=) |
| IL (1) | IL190902A0 (https=) |
| NO (1) | NO20082297L (https=) |
| PE (1) | PE20070711A1 (https=) |
| RU (1) | RU2008119652A (https=) |
| TW (1) | TW200800234A (https=) |
| WO (1) | WO2007050375A2 (https=) |
| ZA (1) | ZA200803454B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0509803A (pt) | 2004-04-13 | 2007-09-18 | Incyte Corp | derivados de piperazinilpiperidina como antagonistas de receptor de quimiocina |
| KR20080064173A (ko) * | 2005-10-21 | 2008-07-08 | 글락소 그룹 리미티드 | 항균제로서 유용한 페리 축합 트리시클릭 화합물 |
| US20080108586A1 (en) * | 2006-09-06 | 2008-05-08 | Incyte Corporation | Combination therapy for human immunodeficiency virus infection |
| WO2010081851A1 (en) | 2009-01-14 | 2010-07-22 | Genoscience Pharma | Piperidin-4-ylpiperazine compounds for the treatment of hcv infection |
| BR112013023050A8 (pt) | 2011-03-09 | 2018-09-25 | G Pestell Richard | antagonista de ccr5, método para determinar se um indivíduo humano tendo câncer de próstata está sofrendo de ou sob o risco de desenvolver metástase, para identificar um antagonista de ccr5, método para determinar se um indivíduo humano tendo câncer de próstata está sofrendo de ou sob o risco de desenvolver metástase, para identificar um composto candidato, para produzir in vitro células epiteliais primárias, para diagnosticar câncer de próstata, para selecionar um tratamento para um indivíduo tendo um câncer/tumor de próstata, linhagem de célula, e, modelo animal |
| GB201118876D0 (en) | 2011-11-01 | 2011-12-14 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| AU2013262977A1 (en) | 2012-05-14 | 2015-01-22 | Prostagene, Llc | Using modulators of CCR5 for treating cancer |
| WO2016094011A1 (en) * | 2014-12-11 | 2016-06-16 | Merck Sharp & Dohme Corp. | Crystal forms of a ccr5 antagonist |
| US12459808B2 (en) | 2021-09-13 | 2025-11-04 | Kabushiki Kaisha Toshiba | Sensor |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6391865B1 (en) * | 1999-05-04 | 2002-05-21 | Schering Corporation | Piperazine derivatives useful as CCR5 antagonists |
| CA2371583C (en) * | 1999-05-04 | 2005-09-13 | Schering Corporation | Piperazine derivatives useful as ccr5 antagonists |
| EP1373206B1 (en) * | 2001-03-29 | 2008-12-24 | Schering Corporation | Aryl oxime-piperazines useful as ccr5 antagonists |
-
2005
- 2005-10-21 US US11/255,643 patent/US7825121B2/en not_active Expired - Fee Related
-
2006
- 2006-10-18 KR KR1020087011479A patent/KR20080058486A/ko not_active Withdrawn
- 2006-10-18 CA CA002626565A patent/CA2626565A1/en not_active Abandoned
- 2006-10-18 AU AU2006306491A patent/AU2006306491B2/en not_active Ceased
- 2006-10-18 CN CNA2006800462485A patent/CN101326178A/zh active Pending
- 2006-10-18 BR BRPI0617731-0A patent/BRPI0617731A2/pt not_active IP Right Cessation
- 2006-10-18 JP JP2008536749A patent/JP2009512705A/ja active Pending
- 2006-10-18 WO PCT/US2006/040636 patent/WO2007050375A2/en not_active Ceased
- 2006-10-18 EP EP06826151.0A patent/EP1951708B1/en active Active
- 2006-10-18 RU RU2008119652/04A patent/RU2008119652A/ru not_active Application Discontinuation
- 2006-10-19 PE PE2006001267A patent/PE20070711A1/es not_active Application Discontinuation
- 2006-10-19 AR ARP060104564A patent/AR058105A1/es not_active Application Discontinuation
- 2006-10-20 TW TW095138842A patent/TW200800234A/zh unknown
-
2008
- 2008-04-15 IL IL190902A patent/IL190902A0/en unknown
- 2008-04-17 EC EC2008008378A patent/ECSP088378A/es unknown
- 2008-04-18 ZA ZA200803454A patent/ZA200803454B/xx unknown
- 2008-05-20 NO NO20082297A patent/NO20082297L/no not_active Application Discontinuation
-
2012
- 2012-01-17 JP JP2012007201A patent/JP2012072195A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2009512705A (ja) | 2009-03-26 |
| KR20080058486A (ko) | 2008-06-25 |
| BRPI0617731A2 (pt) | 2011-08-02 |
| TW200800234A (en) | 2008-01-01 |
| CA2626565A1 (en) | 2007-05-03 |
| ECSP088378A (es) | 2008-05-30 |
| US20060105964A1 (en) | 2006-05-18 |
| NO20082297L (no) | 2008-07-21 |
| IL190902A0 (en) | 2008-11-03 |
| US7825121B2 (en) | 2010-11-02 |
| PE20070711A1 (es) | 2007-08-11 |
| EP1951708B1 (en) | 2013-11-20 |
| WO2007050375A3 (en) | 2007-06-14 |
| WO2007050375A2 (en) | 2007-05-03 |
| AU2006306491A1 (en) | 2007-05-03 |
| ZA200803454B (en) | 2009-04-29 |
| CN101326178A (zh) | 2008-12-17 |
| JP2012072195A (ja) | 2012-04-12 |
| AU2006306491B2 (en) | 2012-12-13 |
| RU2008119652A (ru) | 2009-11-27 |
| EP1951708A2 (en) | 2008-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP099177A (es) | Derivados de quinazolinona e isoquinolinona | |
| NO20083630L (no) | Nye pyridinderivater | |
| LU92550I2 (fr) | Lurasidone, facultativement sous forme de sa base libre ou de ses sels pharmaceutiquement acceptables | |
| ATE495176T1 (de) | Spiroindolinon-derivate | |
| CL2007001752A1 (es) | Compuesto 4-[5(2-amino-etansulfonil)-isoquinolin-7-il]-fenolo una sal farmaceuticamente aceptable o un hidrato o la sal del mismo;composicion farmaceutica que comprende a dicho compuesto,composicion farmaceutica liofilizada;y uso del compuesto como antineiplasico y/o antiviral. | |
| UY30310A1 (es) | Derivados 2-azetidinona, sales, solvatos, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones | |
| CY1117021T1 (el) | Φαρμακευτικες συνθεσεις οι οποιες περιεχουν νιλοτινιβη ή αλας αυτης | |
| ECSP066753A (es) | Antagonistas del receptor de quimiocina | |
| DOP2010000343A (es) | Derivados de quinolinas y quinoxalinas como inhibidores de cinasa de proteina tirosina | |
| MX2010006799A (es) | Benzofuropirimidinonas como inhibidores de la proteina cinasa. | |
| TW200716591A (en) | Novel thiophene derivatives | |
| NO20091395L (no) | Nye tiofenderivater | |
| ECSP11010948A (es) | Inhibidores de las enzimas de proteína cinasa activadas por | |
| CL2008002689A1 (es) | Compuestos derivados de heterociclo 1,4 piperidina sustituida; compuestos intermediarios; composicion farmaceutica; proceso de preparacion; y su uso en el tratamiento del alzheimer y esquizofrenia. | |
| AR054114A1 (es) | Composiciones farmaceuticas que comprenden imatinib y un retardador de la liberacion | |
| CL2011002925A1 (es) | Compuestos derivados de isoquinolin-1(2h)-ona, inhibidores selectivos de la actividad de poli (adp-ribosa) polimerasa parp-1; proceso para prepararlos; composicion farmaceutica; y su uso para tratar una enfermedad mediada por la proteina parp-1. | |
| TW200738670A (en) | Novel thiophene derivatives | |
| ECSP10010303A (es) | (dihidro)pirrolo[2,1-a]isoquinolinas | |
| GT200600163A (es) | Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion | |
| AR049274A1 (es) | Acido2-{[2-(2-metilaminopirimidin-4-il)-1h-indol-5-carbonil]amino}-3-(fenilpiridin-2-ilamino)propionico sustancialmente puro como inhibidor selectivo de la quinasa ikk-2 | |
| ES2531516T3 (es) | Uso de escina | |
| DOP2006000234A (es) | Inhibidores de cinasa | |
| MX2009003169A (es) | Derivados de sulfonamida. | |
| AR058105A1 (es) | Derivados de piperazina utiles como agonistas de ccr5 | |
| ECSP066693A (es) | Derivados de bencimidazol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |